Capítulos de libros (CUN)
Permanent URI for this collectionhttps://hdl.handle.net/10171/70264
See
21 results
Results
- Materiales de elaboración y de acondicionamiento para fórmulas magistrales oftálmicas(SEFH. Sociedad Española de Farmacia Hospitalaria, 2019) Berisa, S. (Silvia); Mondelo-García, C. (Cristina); Macia-Fuentes, L. (Lucas)
- Portal-Mesenteric Venous Thrombosis(Elsevier, 2021) Domínguez-Echávarri, P.D. (Pablo Daniel); Bilbao, J.I. (José I.); Vivas, I. (Isabel); Martinez-Cuesta, A. (Antonio)The importance of portal vein thrombosis (PVT) lies mainly in the complications of prehepatic portal hypertension, which in the chronic state causes bleeding through varices. Acute PVT is the main cause of prehepatic portal hypertension in the Western world1 and the primary cause of portal hypertension of any type in noncirrhotic patients in developed countries. PVT accounts for some 8% to 10% of all cases of portal hypertension.
- Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer(2023) Yamaguchi, K. (Kensei); Loupakis, F. (Fotios); Fakih, M. (Marwan); Kobayashi, K. (Kojiro); Grothey, A. (Axel); Ciardiello, F. (Fortunato); Saxena, F. (Kapil); Di-Bartolomeo, M. (Maria); Masuishi, T. (Toshiki); Raghav, K. (Kanwal); Yoshino, T. (Takayuki); Meinhardt, G. (Gerold); Kawakami, H. (Hisato); Nishina, T. (Tomohiro); Siena, S. (Salvatore); Elez, E. (Elena); Rodríguez-Rodríguez, J. (Javier); Bako, E. (Emarjola); Wainberg, Z. (Zev); Okuda, Y. (Yasuyuki)DESTINY-CRC01 (NCT03384940) was a multicenter, open-label, phase 2 trial assessing the efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients with HER2-expressing metastatic colorectal cancer (mCRC) that progressed after >= 2 prior regimens; results of the primary analysis are published. Patients received T-DXd 6.4mg/kg every 3 weeks and were assigned to either: cohort A (HER2-positive, immunohistochemistry [IHC] 3+ or IHC 2+/in situ hybridization [ISH]+), cohort B (IHC 2+/ISH-), or cohort C (IHC 1+). Primary endpoint was objective response rate (ORR) by independent central review in cohort A. Secondary endpoints included ORR (cohorts B and C), duration of response, disease control rate, progression-free survival, overall survival, pharmacokinetics, and safety of T-DXd. 86 patients were enrolled (53 in cohort A, 15 in cohort B, and 18 in cohort C). Results of the primary analysis are published, reporting an ORR of 45.3% in cohort A. Here, we report the final results. No responses occurred in cohorts B or C. Median progression-free survival, overall survival, and duration of response were 6.9, 15.5, and 7.0 months, respectively. Overall serum exposure (cycle 1) of T-DXd, total anti-HER2 antibody, and DXd were similar regardless of HER2 status. Most common grade >= 3 treatment-emergent adverse events were decreased neutrophil count and anemia. Adjudicated drug-related interstitial lung disease/pneumonitis occurred in 8 patients (9.3%). These findings support the continued exploration of T-DXd in HER2-positive mCRC.
- GLP-1 limits adipocyte inflammation and its low circulating pre-operative concentrations predict worse type 2 diabetes remission after bariatric surgery in obese patients(MDPI AG, 2019) Izaguirre, M. (Maitane); Unamuno, X. (Xabier); Valenti, V. (Víctor); Ramirez, B. (Beatriz); Catalan, V. (Victoria); Becerril, S. (Sara); Frühbeck, G. (Gema); Higuera, M. (Magdalena) de la; Moncada, R. (Rafael); Silva, C. (Camilo); Gomez-Ambrosi, J. (Javier); Salvador, J. (Javier); Rodriguez, A. (Amaia); Monreal, J.I. (José Ignacio)Objective: Glucagon-like peptide (GLP)-1 has been proposed as a key candidate in glucose improvements after bariatric surgery. Our aim was to explore the role of GLP-1 in surgically-induced type 2 diabetes (T2D) improvement and its capacity to regulate human adipocyte inflammation. Methods: Basal circulating concentrations of GLP-1 as well as during an oral glucose tolerance test (OGTT) were measured in lean and obese volunteers with and without T2D (n = 93). In addition, GLP-1 levels were determined before and after weight loss achieved by Roux-en-Y gastric bypass (RYGB) (n = 77). The impact of GLP-1 on inflammation signalling pathways was also evaluated. Results: We show that the reduced (p < 0.05) circulating levels of GLP-1 in obese T2D patients increased (p < 0.05) after RYGB. The area under the curve was significantly lower in obese patients with (p < 0.01) and without (p < 0.05) T2D compared to lean volunteers while obese patients with T2D exhibited decreased GLP-1 levels at baseline (p < 0.05) and 120 min (p < 0.01) after the OGTT. Importantly, higher (p < 0.05) pre-operative GLP-1 concentrations were found in patients with T2D remission after RYGB. We also revealed that exendin-4, a GLP-1 agonist, downregulated the expression of inflammation-related genes (IL1B, IL6, IL8, TNF) and, conversely, upregulated the mRNA levels of ADIPOQ in human visceral adipocytes. Furthermore, exendin-4 blocked (p < 0.05) LPS-induced inflammation in human adipocytes via downregulating the expression and secretion of key inflammatory markers. Conclusions: Our data indicate that GLP-1 may contribute to glycemic control and exert a role in T2D remission after RYGB. GLP-1 is also involved in limiting inflammation in human visceral adipocytes.
- Palliative care professionals’ message to others: an ethnographic approach(MDPI, 2021) Gonçalves, E. (Edna); Centeno, C. (Carlos); Arantzamendi-Solabarrieta, M. (María); Reigada, C. (Carla)Introduction: Palliative care continues to be misunderstood within the world of healthcare. Palliative care professionals are key agents for promoting a greater understanding of their field. This study aims to examine the messages, both implicit and explicit, that palliative care professionals transmit about themselves and their work within their teams and to other health professionals. Methods: Focused ethnographic secondary analysis, exploring the interactions of palliative care professionals as it happens at everyday work. An inductive thematic analysis was developed from 242 h of observation of the daily work practices of palliative care professionals, focusing on their interactions with others. The data was coded without predefined categories, and the analysis was performed independently by two researchers. Results: Palliative professionals communicate that they are part of an active team working in an organized manner. They value and feel proud of their work. Despite the intensity of their work, these professionals are always available to others, to whom they demonstrate a clear professional identity. They convey their expertise in alleviating suffering, respectful behavior and collaborative ability. Conclusion: Professionals, in their daily work, communicate through their messages the essence of palliative care. It is essential that palliative care professionals perceive themselves as potential influencers and explicitly transmit the reasons for their intervention. Otherwise, others will perpetuate the myths, misunderstandings, and lack of a positive reputation for palliative care
- Atlas de cuidados paliativos de Latinoamérica 2020 (2ª ed.)(IAHPC Press, 2021) Steijn, D. (Danny) van; Sánchez-Cárdenas, M. (Miguel); Pons-Izquierdo, J.J. (Juan José); Garralda, E. (Eduardo); Centeno, C. (Carlos); Lima, L. (Liliana) de; Pastrana, T. (Tania)Los cuidados paliativos comenzaron en el Reino Unido durante la década de los sesenta como respuesta a la falta de atención por el sufrimiento físico y emocional de los pacientes con enfermedades incurables y sus seres queridos. Este movimiento comenzó a globalizarse progresivamente, pero aún hoy en muchos lugares del mundo, hospitales, universidades y sistemas de salud prestan mínima atención al enorme problema del sufrimiento asociado a la enfermedad. La enseñanza de las ciencias de la salud, los sistemas sanitarios y hospitales enfatizan enfermedades más que enfermos. Los cuidados paliativos no han recibido la atención ni los fondos necesarios en comparación a disciplinas más jóvenes pero dedicadas al manejo de enfermedades. Una de las formas más útiles de ayudar al desarrollo de los cuidados paliativos es monitorizar la existencia de programas y el progreso de los cuidados paliativos en cada uno de los países de la región. Los datos son mucho más importantes que la retórica para motivar cambio. El Atlas de Cuidados Paliativos en Latinoamérica, y en especial esta segunda edición, demuestra diferencias importantes en el desarrollo de programas y sin duda será muy útil para tanto los líderes paliativos como para los líderes sanitarios, permitirá la adopción de conductas más exitosas que ayuden a desarrollar cuidados paliativos en Latinoamérica y ayudará a unificar futuros criterios para los cuidados paliativos primarios, secundarios y terciarios. Este gran equipo de voluntarios ha trabajado desinteresadamente para generar información que no está disponible en ningún otro registro. Muchos miles de pacientes y sus familias se beneficiarán del gran esfuerzo de este grupo y por ello estoy profundamente agradecido a los colegas y organizaciones que nos permiten un conocimiento profundo del estado de los cuidados paliativos en nuestra región.
- EAPC Atlas of Palliative Care in Europe 2019(EAPC Press, 2019) Mosoiu, D. (Daniela); Pons-Izquierdo, J.J. (Juan José); Garralda, E. (Eduardo); Hasselaar, J. (Jeroen); Centeno, C. (Carlos); Arias-Casais, N. (Natalia); Lima, L. (Liliana) de; Clark, D. (David); Rhee, J.Y. (John Y.); Ling, J. (Julie)
- Additional indicators to assess palliative care development(2019-02-22) Pons-Izquierdo, J.J. (Juan José); Garralda, E. (Eduardo); Centeno, C. (Carlos); Arias-Casais, N. (Natalia); Lima, L. (Liliana) de; López-Fidalgo, J. (Jesús); Rhee, J.Y. (John Y.)This is a short compilation of Health Indicators Assessing the Level of Palliative Care Development at the International Level. These are additional indicators to another published book: Brief Manual on Health Indicators Monitoring Global Palliative Care Development (http://hdl.handle.net/10171/56523).
- Brief manual on health indicators monitoring global palliative care development(IAHPC Press, 2019) Pons-Izquierdo, J.J. (Juan José); Garralda, E. (Eduardo); Centeno, C. (Carlos); Arias-Casais, N. (Natalia); Lima, L. (Liliana) de; López-Fidalgo, J. (Jesús); Rhee, J.Y. (John Y.)
- Atlas de Cuidados Paliativos en Latinoamérica. Edición Cartográfica 2013(International Association for Hospice and Palliative Care (IAHPC), 2013) Pons-Izquierdo, J.J. (Juan José); Centeno, C. (Carlos); Lima, L. (Liliana) de; Pastrana, T. (Tania)El Atlas de Cuidados Paliativos en Latinoamérica es un estudio descriptivo de análisis comparativo de datos y/o estimaciones sobre el desarrollo de servicios e iniciativas de Cuidados Paliativos en Latinoamérica. El desarrollo y modelo del Atlas de Cuidados Paliativos en Latinoamérica se basó en el Atlas de Cuidados Paliativos de la Asociación Europea de Cuidados Paliativos (EAPC). La información se obtuvo por medio de una encuesta semi-estructurada a profesionales de Cuidados Paliativos en cada país. Este instrumento fue elaborado por Tania Pastrana, Carlos Centeno y Liliana De Lima y contó con la asesoría de Isabel Torres. El instrumento fue probado en un estudio piloto con 6 personas y de acuerdo a los resultados se hicieron los cambios necesarios. En esta primera versión del Atlas Latinoamericano de Cuidados Paliativos fueron incluidos 19 países latinoamericanos, con lenguaje oficial español o portugués
- «
- 1 (current)
- 2
- 3
- »